文献速递乳腺癌

家族性乳腺癌风险女性的MRI与乳腺X线筛查比较(FaMRIsc):一项多中心随机对照试验

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2019-06-17

在这项荷兰12家医院的多中心随机对照试验中,1355名有家族性乳腺癌风险的女性随机接受每年MRI联合临床乳腺检查加每两年乳腺X线(MRI组)或每年乳腺X线联合临床乳腺检查(乳腺X线组)。结果显示MRI组检出更多乳腺癌(40例对15例,p=0.0017),浸润癌更小且淋巴结阳性更少,但假阳性可能更多,尤其在高乳腺密度者。

要点

  • MRI组检出乳腺癌40例,乳腺X线组15例(p=0.0017)。
  • MRI组浸润癌中位大小9 mm,乳腺X线组17 mm(p=0.010)。
  • MRI组淋巴结阳性4/24(17%),乳腺X线组5/8(63%)(p=0.023)。

核心结论

  • MRI筛查较乳腺X线在更早期阶段检出癌症,可能减少辅助化疗使用并降低乳腺癌相关死亡率,但优势可能以更多假阳性为代价,尤其在高乳腺密度者。

研究设计与样本

  • 多中心、随机、对照试验,在荷兰12家医院进行,纳入30-55岁、因家族易感性累积终生乳腺癌风险至少20%且BRCA1、BRCA2、TP53野生型女性。
  • 1355名女性同意随机分组,675名分入MRI组、680名分入乳腺X线组;另有231名进入登记组,其中218名在乳腺X线登记组、13名在MRI登记组。
  • MRI组接受每年MRI和临床乳腺检查加每两年乳腺X线,乳腺X线组接受每年乳腺X线和临床乳腺检查;按意向治疗分析。
  • 每名女性平均筛查轮次为4.3(SD 1.76)。

主要发现

  • MRI组检出乳腺癌40例,乳腺X线组15例(p=0.0017)。
  • MRI组浸润癌24例、乳腺X线组8例;MRI组中位大小9 mm(5-14),乳腺X线组17 mm(13-22)(p=0.010)。
  • MRI组淋巴结阳性4/24(17%),乳腺X线组5/8(63%)(p=0.023)。
  • 在 incident 轮次检出的癌症中,MRI组25例中12例(48%)为T1a和T1b期,乳腺X线组15例中1例(7%)为T1a和T1b期(p=0.035);MRI组25例中1例(4%)为T2或更高期,乳腺X线组15例中2例(13%)为T2或更高期。
  • MRI组18例中2例(11%)淋巴结阳性,乳腺X线组8例中5例(63%)淋巴结阳性(p=0.014);所有7例T2或更高期肿瘤均在最高两档乳腺密度类别(乳腺影像报告和数据系统C和D类;p=0.0077)。

局限性

  • MRI筛查方法的优势可能以更多假阳性结果为代价,尤其在高乳腺密度时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 15% of all breast cancers occur in women with a family history of breast cancer, but for whom no causative hereditary gene mutation has been found. Screening guidelines for women with familial risk of breast cancer differ between countries. We did a randomised controlled trial (FaMRIsc) to compare MRI screening with mammography in women with familial risk. METHODS: In this multicentre, randomised, controlled trial done in 12 hospitals in the Netherlands, women were eligible to participate if they were aged 30-55 years and had a cumulative lifetime breast cancer risk of at least 20% because of a familial predisposition, but were BRCA1, BRCA2, and TP53 wild-type. Participants who were breast-feeding, pregnant, had a previous breast cancer screen, or had a previous a diagnosis of ductal carcinoma in situ were eligible, but those with a previously diagnosed invasive carcinoma were excluded. Participants were randomly allocated (1:1) to receive either annual MRI and clinical breast examination plus biennial mammography (MRI group) or annual mammography and clinical breast examination (mammography group). Randomisation was done via a web-based system and stratified by centre. Women who did not provide consent for randomisation could give consent for registration if they followed either the mammography group protocol or the MRI group protocol in a joint decision with their physician. Results from the registration group were only used in the analyses stratified by breast density. Primary outcomes were number, size, and nodal status of detected breast cancers. Analyses were done by intention to treat. This trial is registered with the Netherlands Trial Register, number NL2661. FINDINGS: Between Jan 1, 2011, and Dec 31, 2017, 1355 women provided consent for randomisation and 231 for registration. 675 of 1355 women were randomly allocated to the MRI group and 680 to the mammography group. 218 of 231 women opting to be in a registration group were in the mammography registration group and 13 were in the MRI registration group. The mean number of screening rounds per woman was 4·3 (SD 1·76). More breast cancers were detected in the MRI group than in the mammography group (40 vs 15; p=0·0017). Invasive cancers (24 in the MRI group and eight in the mammography group) were smaller in the MRI group than in the mammography group (median size 9 mm [5-14] vs 17 mm [13-22]; p=0·010) and less frequently node positive (four [17%] of 24 vs five [63%] of eight; p=0·023). Tumour stages of the cancers detected at incident rounds were significantly earlier in the MRI group (12 [48%] of 25 in the MRI group vs one [7%] of 15 in the mammography group were stage T1a and T1b cancers; one (4%) of 25 in the MRI group and two (13%) of 15 in the mammography group were stage T2 or higher; p=0·035) and node-positive tumours were less frequent (two [11%] of 18 in the MRI group vs five [63%] of eight in the mammography group; p=0·014). All seven tumours stage T2 or higher were in the two highest breast density categories (breast imaging reporting and data system categories C and D; p=0·0077) One patient died from breast cancer during follow-up (mammography registration group). INTERPRETATION: MRI screening detected cancers at an earlier stage than mammography. The lower number of late-stage cancers identified in incident rounds might reduce the use of adjuvant chemotherapy and decrease breast cancer-related mortality. However, the advantages of the MRI screening approach might be at the cost of more false-positive results, especially at high breast density. FUNDING: Dutch Government ZonMw, Dutch Cancer Society, A Sister's Hope, Pink Ribbon, Stichting Coolsingel, J&T Rijke Stichting.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Saadatmand S, Geuzinge HA, Rutgers EJT, et al. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncol. 2019. PMID: 31221620. doi:10.1016/S1470-2045(19)30275-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。